Orexo

Uppsala, Sweden – June 30, 2025 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces that, during June 2025, the number of shares and votes in the company has changed as a result of the issue and repurchase of class C shares as announced on June 18, 2025. In total, the number of shares has increased by 2,446,000 class C shares and the votes have increased by 244,600.

Today, the last trading day of the month, there are in total 37,156,639 shares in Orexo - whereof 34,710,639 are ordinary shares with one vote per share and 2,446,000 are class C shares with one tenth of a vote per share. The total number of votes in the company is 34,955,239.

For further information contact:
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US.

For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.